Q1 FY27 Results: Net Profit Falls 52 Percent YoY to Rs. 398 Lakhs

Ebitda Margin CompressionExceptional ItemResults View source PDF Explain this filing

AMBALALSA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.3%Reaction day

₹44.72

prior close

₹42.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-8.5% vs market

Pharmaceuticals peers, median of 166sector+0.1%-8.4% vs sector

On the reaction day the stock moved 8.5 pts less than Nifty Microcap 250 and 8.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.6

10m

-0.7

15m

-2.7

30m

-3.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.3+0.2-8.5+0.1-8.4

Next day

-6.1+0.2-6.3-0.2-5.9

+2.2+0.4+1.8-0.2+2.4

+7.0+0.7+6.3-0.4+7.5

+4.4+0.1+4.3-1.5+5.9

+8.0+0.7+7.3-0.9+8.8

-1.6+1.2-2.8-0.5-1.1

15d

-2.4+0.7-3.2+0.3-2.8

-13.2-1.2-12.0-0.0-13.2

-13.9-1.1-12.8-2.3-11.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q1 FY27 consolidated results. Revenue from operations rose to Rs. 4,356 lakhs from Rs. 4,034 lakhs. Net profit fell 52 percent YoY to Rs. 398 lakhs versus Rs. 822 lakhs, hurt by lower other income (Q1 FY26 had a Rs. 665 lakh one-time sales tax reversal). PBT was Rs. 468 lakhs. EPS at Rs. 0.52 versus Rs. 1.07. Electronics segment revenue grew 23 percent to Rs. 1,833 lakhs. Pharmaceuticals revenue was nearly flat at Rs. 2,526 lakhs. Statutory auditors issued an unqualified review report.

Likely market impact

Profit decline mainly reflects an unfavorable year-on-year comparison from a one-time tax reversal in the base, not core weakness. Margins remain under pressure.